Clinical characteristics of seborrheic dermatitis in HIV-infected patients


DOI: https://dx.doi.org/10.18565/epidem.2020.10.1.41-7

Evdokimov E.Yu., Ponezheva Zh.B., Gorelova Е.А., Sundukov A.V.

1) Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2) A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
Objective. To identify the clinical characteristics of seborrheic dermatitis (SD) in HIV-infected patients according to HIV infection stage, immune status, and viral load.
Subjects and methods. A total of 401 patients with SD were followed up. A study group included 198 (49.4%) HIV-infected patients; a comparison group consisted of 203 (50.6%) HIV-negative patients. The dermatology index (Perioral Dermatitis Severity Index (PODSI)/ITPOD) was determined to assess the severity of SD symptoms. In addition to conventional studies, the investigators determined HIV RNA levels by PCR on an iCycler (Austria), by using the AmpliSens HIV-Monitor test system (Central Research Institute of Epidemiology of Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Russia) and estimated the counts of CD3+, CD4+, and CD8+ lymphocyte subpopulations on a FACS Calibur flow cytometer (Becton Dickinson, USA).
Results. The onset or exacerbation of skin disease was observed in 372 (92.7%) patients within 6 months to 3 years before their inclusion in the study. The progression/exacerbation of SD at the stage of secondary diseases was noted in 140 (76.5%) patients of the study group. The process was sluggish and continuously recurring in 33.5% of cases. The concurrence of the two skin pathologies was observed in 46.1% of patients in both groups, while the compatibility was 73.2% in the study group. At the beginning of the study, obvious immunodeficiency was seen in patients at the stage of secondary diseases (the CD4+ lymphocyte counts was less than 350 cells/ml in 101 patients), while the viral load was more than 103 copies for HIV RNA; 71 patients were noted to have moderate-to-severe and severe SD requiring continuous drug therapy.
Conclusion. Taking into account the correlation of the intensity of cutaneous manifestations of SD with the clinical stage of HIV infection, viral load, and CD4+ lymphocyte counts, the quantitative and qualitative assessment of the recording of morphological alterations of the skin can serve as a prognostic criterion for the course of HIV infection.
Keywords: perioral dermatitis severity index, Keyword: seborrheic dermatitis, viral load, HIV infection
Read entire article

Literature


  1. Федеральные клинические рекомендации. Дерматове­нерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М.: Деловой экспресс, 2016. 768 с.

    [Federal Clinical Guidelines. Dermatology 2015: diseases of the skin. Sexually transmitted infections]. 5th ed. Moscow: Delovoj Express, 2016. 768 p. (In Russ).



  2. Zander N., Sommer R., Schäfer I., Reinert R., Kirsten.,Zyriax B.C., Maul J.T., Augustin M. Epidemiology and dermatological comorbidity of seborrhoeic dermatitis: population-based study in 161 269 employees. Br. J. Dermatol. 2019; 181(4): 743–8. DOI: 10.1111/bjd.17826.

  3. Berk T., Scheinfeld N. Seborrheic Dermatitis. P&T. 2010; 35(6): 348–52.

  4. Borda L.J., Wikramanayake T.C.. Seborrheic Dermatitis and Dandruff: A Comprehensive Review. J. Clin. Investig. Dermatol. 2015; 3(2). DOI: 10.13188/2373-1044.1000019

  5. Dessinioti C., Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin. Dermatol. 2013; 31(4): 343–51. DOI: 10.1016/j.clindermatol.2013.01.001.

  6. Голдсмит Л.А., Кац С.И., Паллер Э.С., Леффель Д.Дж., Вольф К. Дерматология Фицпатрика в клинической практике. Пер. с англ. 2-е изд., перераб. и доп. М.: Издательство Панфилова; БИНОМ, 2015. Т.1: 286–94.

    Goldsmith L.A., Katz S.I., Paller A.S., Leffell D.J., Wolf K. [Fitzpatrick dermatology in clinical practice]. 2nd ed. Moscow: Panfilov Publ.; BINOM, 2015. Vоl. 1: 286–94. (In Russ).



  7. Ameen M. The impact of human immunodeficiency virus-related diseases on pigmented skin types. Br. J. Dermatol. 2013; 169(Suppl 3): 11–8. DOI: 10.1111/bjd.12527.

  8. Menche J., Sharma A., Kitsak M., Ghiassian S.D., Vidal M., Loscalzo J. Uncovering disease-disease relationships through the incomplete human interactome. Science 2015; 347(6224): 1257601. DOI: 10.1126/science.1257601

  9. Адаскевич В.П. Диагностические индексы в дерматологии. М.: Издательство Панфилова; БИНОМ. Лаборатория знаний. 2014. 352 с.

    Adaskevich V.P. [Diagnostic indices in dermatology]. Moscow: Panfilov Publ.; BINOM. Knowledge laboratory. 2014. 352 р. (In Russ).



  10. Wollenberg A., Oppel T. Scoring of Skin Lesions with the Perioral Dermatitis Severity Index (PODSI). DOI: 10.2340/00015555-0044. https://www. medicaljournals.se/acta/download/10.2340/00015555-0044/

  11. Национальные рекомендации по диспансерному наблюдению и лечению больных ВИЧ-инфекцией. Клинический протокол. Эпидемиол. инфекц. болезни. Актуал. вопр. 2016; 6 (приложение): 1–72.

    [National recommendations for clinical monitoring and treatment of patients with HIV infection. Clinical protocol]. Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2016; 6(Suppl.): 1–72. (In Russ.).



  12. Garg T., Sanke S. Inflammatory dermatoses in human immunodeficiency virus. Indian J. Sex. Transm. Dis. AIDS 2017; 38(2): 113–20.

  13. Prabhakaran N., Telanseri J.J., Hamide A., Malathi M., Kumari R., Thappa D.M. Effect of antiretroviral therapy on mucocutaneous manifestations among Human Immunodeficiency Virus-infected patients in a tertiary care centre in South India. Indian J. Sex. Transm. Dis. AIDS 2015; 36(2): 166–73.

  14. Ramdial P.K., Grayson W. Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS)-associated cutaneous diseases. In: Calonje E., Brenn T., Lazar A., McKee P.H. (eds.). McKee’s Pathology of the Skin. 4th edition. eBook ISBN: 9780723437185 Philadelphia, Pa, USA: Elsevier,2011.


About the Autors

Yevgeny Yu. Evdokimov, Cand. Med. Sci., Researcher, Clinical Department, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; e-mail: evdokimovevg@yandex.ru; ORCID: http//orcid.org/0000-0003-2694-8900
Prof. Zhanna B. Ponezheva, MD, Head, Clinical Department, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; е-mail: doktorim@mail.ru; ORCID: http//orcid.org/0000-0002-6539-4878
Elena A. Gorelova, Cand. Med. Sci., Researcher, Clinical Department, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; е-mail: doctorgorelovaea@yandex.ru; ORCID: http//orcid.org/0000-0002-3861-6375
Aleksandr V. Sundukov, MD, Professor, Department of Infectious Diseases and Epidemiology, A.I. Evdokimov Moscow State Medical Stomatological University, Moscow, Russia: е-mail: sunducov1961@mail.ru; ORCID: http// orcid.org/0000-0002-3798-7780


Similar Articles

Back to Content

Бионика Медиа